| First Author | Mou X | Year | 2020 |
| Journal | Mol Med Rep | Volume | 22 |
| Issue | 5 | Pages | 3785-3794 |
| PubMed ID | 32901868 | Mgi Jnum | J:305695 |
| Mgi Id | MGI:6705276 | Doi | 10.3892/mmr.2020.11486 |
| Citation | Mou X, et al. (2020) A novel identified circular RNA, circ_0000491, aggravates the extracellular matrix of diabetic nephropathy glomerular mesangial cells through suppressing miR101b by targeting TGFbetaRI. Mol Med Rep 22(5):3785-3794 |
| abstractText | Circular RNAs (circRNAs) have crucial roles in various diseases; however, the mechanisms of action underlying circRNAs in the occurrence and development of diabetic nephropathy (DN) remains largely unknown. The present study investigated the differentially expressed circRNAs in the DN mice kidney cortex using circRNA sequencing and elucidated the role of circRNAs in mesangial cells. It was revealed that 40 circRNAs were unconventionally expressed, including 18 upregulated circRNAs and 22 downregulated circRNAs. Furthermore, circ_0000491 levels were significantly augmented in both DN mice and high glucose (HG, 30 mM)induced mouse mesangial cells (MES13 cells). Knockdown of circ_0000491 significantly suppressed the increase of vimentin, fibronectin and alphasmooth muscle actin, as well as collagen type I, III and IV, whilst reversing the decrease of Ecadherin in HGinduced MES13 cells. It was further revealed that circRNA_0000491 sponged miR101b and that miR101b directly targets TGFbetaRI. In addition, the expression levels of miR101b were negatively associated with the transcriptional level of circRNA_0000491 and miR101b inhibitors reversed the suppression of extracellular matrix (ECM)associated protein synthesis mediated by knockingdown circRNA_0000491. In conclusion, the present study investigated the circRNA_0000491/miR101b/TGFbetaRI axis in ECM accumulation and fibrosisassociated protein expression levels of mesangial cells, which suggested that circRNA_0000491 may be beneficial for the development of an effective therapeutic target for DN. |
